March 17 (Reuters) - Indian drugmakers Zydus Lifesciences and Lupin have signed a licensing and supply deal on Tuesday to ...

Zydus Lifesciences and Lupin have entered into a licensing and supply agreement to co‑market a semaglutide injection in India ...

Under the Licensing and Supply Agreement signed by both companies, Lupin will have semi-exclusive rights to co-market Zydus’ ...

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to ...

Lupin and Zydus ink licensing agreement to co-market innovative semaglutide injection in India: Our Bureau, Mumbai Tuesday, March 17, 2026, 14:30 Hrs [IST] Global pharma major Lup ...

Add Yahoo as a preferred source to see more of our stories on Google. First conceived by the manga artist Monkey Punch (aka Katō Kazuhiko) in 1967, the impish and uncatchable gentleman thief Lupin the ...

Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced ...

As part of the deal, Lupin will pay Zydus upfront licensing fees and milestone-based payments linked to predefined targets.

On Friday, a post on the official X (formerly Twitter) account for the Lupin the 3rd franchise announced a new animated movie set to come out next year. The film, tentatively titled Lupin the IIIrd ...

Semaglutide is a GLP-1 receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping ...

Lupin's first computer-generated adventures loses some of his franchise's romantic aura, but it would take more than that to steal his mojo. First conceived by the manga artist Monkey Punch (aka Katō ...